Mike Mortimer

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV, Ningbo My-BioMed Biotechnology Co.,Ltd., CancerRop Co. Ltd., and the University of Oxford. Oxford Cancer Biomarkers range of predictive biomarkers will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 20 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. OncoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer.

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Global Healthcare Opportunities, or GHO Capital, was founded in 2014 as a specialist healthcare investment adviser based in London. The firm was built from a shared experience and long-standing history of creating and backing businesses, accelerating growth, delivering value and championing success in the sector through prior roles with healthcare industry leader Quintiles, 3i Group, J.P. Morgan and TPG. We actively evaluate companies with a European presence and global potential within the four healthcare sub-sectors of Outsourced services, PharmaBio, MedTech and Patient services. Our sourcing strategy is based upon a combination of expert healthcare sub-sector knowledge and a global network of industry relationships. Our experienced leadership team brings a unique fusion of private equity, investment banking and industry competencies. The team is designed to provide insight and expertise in supporting company growth and maximising potential. We work alongside management teams who benefit from our proprietary insight and unfettered access to our unique global platform of experience, resource and expert networks. For more information please visit www.ghocapital.com.

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV, Ningbo My-BioMed Biotechnology Co.,Ltd., CancerRop Co. Ltd., and the University of Oxford. Oxford Cancer Biomarkers range of predictive biomarkers will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 20 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. OncoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer.